Other Information.
+Added: Trading Plans
+Added: On August 15, 2025 , our Chief Medical Officer , Mark Schoenberg , entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5 - 1 (c) under the Exchange Act, to sell up to 40,000 ordinary shares.
+Added: The trading plan expires on November 18, 2026.
+Added: Agenus License Agreement Termination
+Added: November 2025, we provided notice to terminate the license agreement with Agenus in connection with our decision to discontinue development of UGN-
+Added: Under the terms of the license agreement, following notice of termination, the agreement will terminate upon the later of (a) the expiration of a
+Added: 180 -day notice period;
+Added: or (b) completion of all wind-down activities and delivery of all Agenus Improvements (as defined in the license agreement) to Agenus.
+Added: not expect to incur any costs in connection with the termination of the agreement.
+Added: Lease Extension
+Added: August 8, 2025, we entered into an amendment to our lease agreement, dated
+Added: November 4, 2019, between us and Witman Properties, L.L.C.
+Added: and Alexander Road at Davanne, L.L.C.
+Added: (collectively, the “Landlord”).
+Added: Pursuant to the amendment, we extended the expiration date of the lease from
+Added: January 31, 2026 to
+Added: April 30, 2031.
+Added: Commencing with the extension term on
+Added: February 1, 2026, our base rent will be approximately
+Added: $0.6 million per year, or approximately
+Added: $3.0 million in total during the extension term.
+Added: The foregoing summary of the lease amendment is qualified in its entirety by reference to the lease amendment, a copy of which is filed as Exhibit
+Added: 10.1 to this Quarterly Report.
The following exhibits are filed as part of this report:
1 unchanged sentence
001-38079), filed with the SEC on May 18, 2017).
−Removed: 2019 Inducement Plan, as amended.
+Added: Amendment to Lease Agreement, dated August 8, 2025, by and between the Registrant and Witman Properties, L.L.C.
+Added: and Alexander Road at Davanne, L.L.C.
Certification of Principal Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
11 unchanged sentences
The cover page from the Company’s Quarterly Report on Form 10-Q has been formatted in Inline XBRL
−Removed: Management contract or compensatory plan.
The information in Exhibits 32.1 and 32.2 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Quarterly Report), unless the Registrant specifically incorporates the foregoing information into those documents by reference.
1 unchanged sentence
UroGen Pharma Ltd.
−Removed: August 7, 2025
+Added: November 6, 2025
/s/ Elizabeth Barrett
2 unchanged sentences
(Principal Executive Officer)
−Removed: August 7, 2025
+Added: November 6, 2025
/s/ Chris Degnan
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.